Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 8/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 4/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | CDK7 | P50613 | 2/20 | 0.48 |
| ▸ | CIT | O14578 | 1/20 | 0.48 |
| ▸ | CASK | O14936 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.48 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22494766 | 0.85 | RAB9A (0.47) | RAB9ASMN1; SMN2CNR2CDK2CCNE2 | |
| SCHEMBL22494694 | 0.82 | CNR2 (0.45) | RAB9ASMN1; SMN2CNR2CDK2CCNE2 | |
| SCHEMBL22494688 | 0.82 | CNR2 (0.45) | RAB9ASMN1; SMN2CNR2CDK2CCNE2 | |
| SCHEMBL22494687 | 0.82 | CNR2 (0.45) | RAB9ASMN1; SMN2CNR2CDK2CCNE2 | |
| SCHEMBL179490 | 0.80 | CCNE1 (0.52) | CNR2CDK2CCNE2CCNE1CCNB2 | |
| SCHEMBL17632088 | 0.80 | UCHL1 (0.64) | RAB9ACNR2CDK2CCNE2CCNE1 | |
| SCHEMBL20270816 | 0.76 | SMN1; SMN2 (0.58) | RAB9ASMN1; SMN2CDK2CCNE1LCK | |
| SCHEMBL20877512 | 0.75 | CA1 (0.47) | CNR2CDK2CCNE2CCNE1LCK | |
| SCHEMBL13436517 | 0.75 | CDK2 (0.65) | RAB9ASMN1; SMN2CDK2CCNE1LCK | |
| SCHEMBL19261385 | 0.75 | CCND3 (0.43) | RAB9ASMN1; SMN2CNR2CDK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | RAB9A 2402/4885SMN1; SMN2 1940/4885CNR2 279/4885 |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | CYP3A43, CYP2F1, CYP11B2 | RAB9A 1189/4885SMN1; SMN2 2425/4885CNR2 238/4885 |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | CYP3A43, CYP2F1, CYP11B2 | RAB9A 1189/4885SMN1; SMN2 2425/4885CNR2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.